risedronic acid has been researched along with Graves Disease in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Majima, T | 1 |
| Komatsu, Y | 1 |
| Doi, K | 1 |
| Takagi, C | 1 |
| Shigemoto, M | 1 |
| Fukao, A | 1 |
| Morimoto, T | 1 |
| Corners, J | 1 |
| Nakao, K | 1 |
1 trial available for risedronic acid and Graves Disease
| Article | Year |
|---|---|
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Di | 2006 |